Effect of the Human Papilloma Vaccine on cervical cancer prevention: Meta-analysis

Abstract

The aim of this review is to analyze and evaluate the efficacy of the prophylactic vaccine againsthuman papilloma virus to prevent cervical cancer. This was accomplished through a research in MEDLINE forcontrolled and randomized clinical trials that evaluated the efficacy of the bivalent and quadrivalent vaccineagainst the development of CIN lesions. The bivalent vaccine Cervarix lowered the risk 19.35% (0.24 [0.130.44]), the active bivalent 2% (0.02 [0.00-0.28). The quadrivalent vaccine Gardasil 16% (0.19 [0.08-0.48]) andthe active quadrivalent 3% (0.03 [0.01-0.08). These results show that the treatment group always had apositive outcome compared to the control group and both vaccines are effective to reduce the developmentof CIN+ lesions.